Please login to the form below

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published the 21st edition of the EML, recommending the inclusion of 28 new medicines.

The new additions were selected through an evidence-based process which assesses the quality, safety, efficacy and cost-effectiveness of candidate treatments. For the 2019 update, the Expert Committee evaluated a total of 65 applications, including proposals to add new medicines, extend the indication of listed treatments and remove medicines from the list.

The criteria

In 2018, The WHO Cancer Medicines Working Group (CMWG) adopted the European Society for Medical Oncology‒Magnitude of Clinical Benefit Scale (ESMO–MCBS) as a screening tool to identify cancer treatments that demonstrate therapeutic value. The CMWG indicated that for therapies to become eligible for inclusion in the EML, they need to show an ESMO score equal to 4, 5 or A–B, provided that the clinical benefits meet or exceed the 4–6-month survival interval.

Cancer treatments recommended for listing:

International nonproprietary name (INN)

Brand name






Bristol-Myers Squibb

Front-line monotherapy in patients with unresectable and metastatic melanoma

Merck’s Keytruda (pembrolizumab) was indicated as a therapeutically equivalent alternative




Treatment of patients with

newly diagnosed multiple myeloma in both non-transplant and transplant eligible/available settings









Multiple brands





Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer

Boehringer Ingelheim’s Gilotrif (afatinib) and AstraZeneca’s Iressa (gefitinib) were indicated as a therapeutically equivalent alternative




Treatment of patients with metastatic castration-resistant prostate cancer





Treatment of patients with

acute promyelocytic leukaemia




Sigma Tau


A number of high-profile rejections were also reported in the latest WHO EML, including:

  • Non-small cell lung cancer treatments, due to their still-evolving place in therapy:
  • Bristol-Myers Squibb’s Opdivo® (nivolumab)
  • Merck’s Keytruda® (pembrolizumab)
  • Genentech’s Tecentriq (atezolizumab)
  • HER-2 positive breast cancer treatments:
    • Genentech’s Perjeta® (pertuzumab)
      due to lack of sufficient evidence to demonstrate a clinically meaningful overall survival benefit in early-stage disease.
    • Roche’s Kadcyla® (trastuzumab emtansine)
      the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority in the context of treatment of breast cancer.

Narrowing the gap to effective treatment access

The inclusion of innovative medicines in the WHO EML is an important step to help patients gain access to effective treatments. The WHO EML influences other essential medicines lists at the national and regional level, and, therefore, which medicines are kept in stock and available by the government. According to the WHO, more than 150 countries use the EML to guide decisions about which medicines represent the best value for money.

To read the rest of the blog visit:

22nd October 2019



Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

152-160 City Road
Kemp House
United Kingdom

Latest content on this profile

Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
Using TRAVELLESS™ to provide tailored pharmaceutical training
In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
The vicious circle of pharmaceutical tendering
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight